Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Study of AST-OPC1 in Spinal Cord Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Major Inclusion Criteria:~* Sensorimotor complete, traumatic SCI (ASIA Impairment Scale A) for cohorts 1,2,3~* Sensorimotor incomplete, traumatic SCI (ASIA Impairment Scale B) for cohorts 4,5~* Last fully preserved single neurological level (SNL) from C-4 to C-7~* From 18 through 69 years of age at time of injury~* Single spinal cord lesion on a post-stabilization magnetic resonance imaging (MRI) scan, with sufficient visualization of the spinal cord injury epicenter and lesion margins to enable post-injection safety monitoring~* Informed consent for this protocol and the companion long term follow-up protocol must be provided and documented (i.e., signed informed consent forms) no later than 37 days following injury~* Able to participate in an elective surgical procedure to inject AST-OPC1 21-42 days following SCI~Major Exclusion Criteria:~* SCI due to penetrating trauma~* Traumatic anatomical transection or laceration of the spinal cord based on prior surgery or MRI~* Any concomitant injury that interferes with the performance, interpretation or validity of neurological examinations~* Inability to communicate effectively with neurological examiner such that the validity of patient data could be compromised~* Significant organ damage or systemic disease that would create an unacceptable risk for surgery or immunosuppression~* History of any malignancy (except non-melanoma skin cancers)~* Pregnant or nursing women~* Body mass index (BMI) \> 35 or weight \> 300 lbs.~* Active participation in another experimental procedure/intervention

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- AST-OPC1 (Type: EXPERIMENTAL): Open label, dose escalation, cross-sequential cohort of subjects who receive an injection or two injections of AST-OPC1 at a single time-point

Based on this trial design, predict the completion outcome and termination type (if applicable).